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Objective: To present ﬁrst-trimester molecular diagnosis of complete hydatidiform mole (CHM) associ-
ated with dizygotic twin pregnancy conceived by intrauterine insemination.
Materials and methods: A 32-year-old woman presented to the hospital with a huge complex cystic mass
measuring about 8.5 cm  4.1 cm in the uterine cavity and a living co-existing fetus with fetal biometry
equivalent to 9 weeks. She underwent chorionic villus sampling at 13 weeks of gestation, and micro-
satellite genotyping for molar pregnancy test was applied. A molar pregnancy test was performed by a
short tandem repeat (STR) identiﬁer polymerase chain reaction (PCR) polymorphic marker analysis. The
pregnancy was terminated at 14 weeks of gestation. Postnatal polymorphic DNA marker analysis of the
placenta by quantitative ﬂuorescent PCR (QF-PCR) was performed. Analysis of maternal blood total b-
human chorionic gonadotropin revealed a high level of 551,600 mIU/mL at 10 weeks of gestation and a
level of 1.0 mIU/mL at 15 weeks postpartum. The woman was doing well at 4 months after delivery.
Results: The results of STR identiﬁer PCR polymorphic marker analysis showed androgenic conception in
the complex cystic mass and biparental conception in the living fetus. Pathological analysis of the cystic
mass conﬁrmed the diagnosis of CHM. The results of QF-PCR showed biparental inheritance in the
normal fetus and complete paternal homozygosity in the CHM of the abnormal fetus in all STRs, indi-
cating dizygotic twinning and CHM of monospermy.
Conclusion: Prenatal sonographic diagnosis of placentomegaly with many grape-like vesicles should
include a differential diagnosis of CHM, partial hydatidiform mole (PHM), placental mesenchymal
dysplasia (PMD), and recurrent hydatidiform mole. Microsatellite genotyping for molar pregnancy
testing and zygosity testing is useful in cases of prenatal diagnosis of placentomegaly associated with
many grape-like vesicles and a twin pregnancy with a living fetus in the ﬁrst trimester.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.s and Gynecology, Mackay
oad, Taipei, Taiwan.
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bstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Complete hydatidiform mole (CHM) associated with twin
pregnancy and a normal fetus is very rare, and has an estimated
incidence from 1 in 20,000 to 1 in 100,000 pregnancies [1,2].
CHM with twin pregnancy and a normal co-existing fetus can be
associated with fetomaternal complications such as persistent
gestational trophoblastic disease, vaginal bleeding, thromboem-
bolic disease, hyperemesis, intrauterine fetal death, and even
uterine rupture [1,3e6]. CHM has been associated with advanced
maternal age and assisted reproductive technology such as
in vitro fertilization and intracytoplasmic sperm injection
[4,7e15]. Shazly et al [16] previously reported a case of twin
pregnancy with CHM and co-existing fetus following ovulation
with a non-prescribed clomiphene citrate. Here, we present our
experience of ﬁrst-trimester molecular diagnosis of CHM associ-
ated with dizygotic twin pregnancy conceived by intrauterine
insemination.Materials and methods
Clinical description
A 32-year-old, gravida 2, para 1, woman presented to the
hospital at 9 weeks of gestation with a huge complex cystic mass
measuring about 8.5 cm  4.1 cm in the uterine cavity and a living
co-existing fetus with fetal biometry equivalent to 9 weeks (Fig. 1).
Her husband was 37 years of age. The woman had a 4-year-old
healthy son, and this pregnancy was conceived by intrauterine
insemination. She underwent chorionic villus sampling atFig. 1. Prenatal ultrasound at 9 weeks of gestation shows a huge complex cystic mass
(arrow) and a living co-existing fetus.13 weeks of gestation, and microsatellite genotyping for molar
pregnancy test was applied. A molar pregnancy test was per-
formed by a short tandem repeat (STR) identiﬁer polymerase
chain reaction (PCR) polymorphic marker analysis. The results
were consistent with the diagnosis of CHM associated with dizy-
gotic twin pregnancy. The pregnancy was terminated at 14 weeks
of gestation. The living female fetus was normal. Pathological
analysis of the cystic mass conﬁrmed the diagnosis of CHM.
Postnatal polymorphic DNA marker analysis of the placenta by
quantitative ﬂuorescent PCR (QF-PCR) conﬁrmed the prenatal
diagnosis. Analysis of maternal blood total b-human chorionic
gonadotropin revealed a high level of 551,600 mIU/mL at 10 weeks
of gestation (normal: 10,000e100,000 mIU/mL at 8e12 weeks), a
level of 99,563 mIU/mL on the day after delivery of the placenta, a
level of 1986 mIU/mL at 1 week postpartum, a level of 357.5 mIU/
mL at 2 weeks postpartum, a level of 140.4 mIU/mL at 3 weeks
postpartum, a level of 21.8 mIU/mL at 7 weeks postpartum, a level
of 5.5 mIU/mL at 11 weeks postpartum, and a level of 1.0 mIU/mL
at 15 weeks postpartum. The woman was doing well at 4 months
after delivery.STR identiﬁer PCR polymorphic marker analysis
STR identiﬁer PCR polymorphic marker analysis was performed
on the DNA extracted from the placental tissues obtained prena-
tally by chorionic villus sampling. This analysis contains ﬂuo-
rescently labeled primers for sex determination marker or
amelogenin and 15 STR markers of D21S1437 (21q21.1), D22S683
(22q12.3), D8S1110 (8q11.23), D10S2325 (10p13), D12S1090
(12q13.3), D17S1294 (17q11.2), Penta D (21q22.3), D3S1744 (3q24),
D14S608 (14q12), D20S470 (20p12.1), Penta E (15q26.2), D4S2366
(4p16.1), D18S536 (18q12.1), D13S765 (13q14.11), and D6S474
(6q21).QF-PCR analysis
QF-PCR analysis was performed on the DNA extracted from
the placental tissues obtained postnatally by placental samplings.
This analysis contains uncultured ﬂuorescently labeled STR
markers of D13S768 (13q21.1), D18S877 (18q12.1), and D21S2049
(21q22.11).Table 1
Microsatellite genotyping using amelogenin and 15 small tandem repeat (STR)
markers.a




D21S1437 21q21.1 14/14 14/16 14 14/14
D22S683 22q12.3 14.2/20.2 13/15.2 14.2 13/14.2
D8S1110 8q11.23 26/27 26/26 27 26/26
D10S2325 10p13 11/13 11/11 13 11/13
D12S1090 12q13.3 6/12 9/13 6 6/9
D17S1294 17q11.2 15/15 14/15 15 14/15
Penta D 21q22.3 9/9 9/11 9 9/11
D3S1744 3q24 14/19 17/20 19 14/20
D14S608 14q12 7/10 6/12 10 7/12
D20S470 20p12.1 14/17 10/16 14 16/17
Penta E 15q26.2 10/21 11/16 10 10/11
D4S2366 4p16.1 11/12 9/12 11 9/11
D18S536 18q12.1 11/12 11/12 11 11/11
D13S765 13q14.11 8/9 9/9 8 9/9
D6S474 6q21 13/14 13/13 14 13/14
a Each algebraic number represents a speciﬁc allele with a speciﬁc base pair size
in a speciﬁc STR marker.
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The CHM tissues and the placental tissues of a normal fetus were
sent for pathological examination by hematoxylin and eosin (H& E)
stain at the power of 10 and 40, respectively.Fig. 2. Representative electrophoretograms of microsatellite genotyping using small tandem
D8S1110 (8q11.23). The results show twin females, androgenic conception in the abnormal fe
the diagnosis of complete hydatidiform mole (CHM) associated with dizygotic twin pregnan
the father inherits 14.2 and 20.2, and the normal fetus inherits one allele of 13 from the mo
only the paternal allele of 14.2.Results
The results of STR identiﬁer PCR polymorphic marker analysis
showed androgenic conception in the complex cystic mass and
biparental conception in the living fetus (Table 1). For example, inrepeat (STR) markers of amelogenin or A, D21S1437 (21q21.1), D22S683 (22q12.3), and
tus (mole), and biparental conception in the living fetus. The results are consistent with
cy. For example, in the marker D22S683, the mother inherits the alleles of 13 and 15.2,
ther and one allele of 14.2 from the father, but the CHM in the abnormal fetus inherits
Fig. 3. Representative electrophoretograms of microsatellite genotyping using small tandem repeat (STR) markers of D3S1744 (3q24), D14S608 (14q12), D20S470 (20p12.1), and
Penta E (15q26.2). The results show androgenic conception in the abnormal fetus (mole) and biparental conception in the living fetus. The results are consistent with the diagnosis
of complete hydatidiform mole (CHM) associated with dizygotic twin pregnancy. For example, in the marker D3S1744, the mother inherits the alleles of 17 and 20, the father
inherits 14 and 19, and the normal fetus inherits one allele of 14 from the father and one allele of 20 from the mother, but the CHM in the abnormal fetus inherits only the paternal
allele of 19.
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15.2, the father inherits 14.2 and 20.2, and the normal fetus in-
herits one allele of 13 from the mother and one allele of 14.2 from
the father, but the CHM in the abnormal fetus inherits only the
paternal allele of 14.2 (Fig. 2). For example, in the markerD3S1744, the mother inherits the alleles of 17 and 20, the father
inherits the alleles of 14 and 19, and the normal fetus inherits one
allele of 14 from the father and one allele of 20 from the mother,
but the CHM in the abnormal fetus inherits only the paternal
allele of 19 (Fig. 3). Pathological analysis of the cystic mass
Fig. 4. (A) The gross appearance of complete hydatidiform mole (CHM). (B) Histo-
logical lower power view [10, hematoxylin and eosin (H&E) stain] of CHM shows
numerous edematous chorionic villi with cistern formation, and (C) histological higher
power view (40, H&E stain) of CHM shows hyperplastic trophoblasts.
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cystic mass showed numerous edematous chorionic villi with
cistern formation in the lower power view and hyperplastic
trophoblasts in higher power view (Fig. 4). The results of QF-PCRshowed biparental inheritance in the normal fetus and complete
paternal homozygosity in the CHM of the abnormal fetus in all
STRs, indicating dizygotic twinning and CHM of monospermy
(Fig. 5). For example, in the marker D13S768 (13q21.1), the father
inherits the allele of 150 bp, the mother inherits the allele of
155 bp, and the normal fetus inherits one allele of 150 bp from
the father and one allele of 155 bp from the mother, but the CHM
in the abnormal fetus inherits only the paternal allele of 150 bp.Discussion
Prenatal sonographic diagnosis of placentomegaly with many
grape-like vesicles should include a differential diagnosis of CHM,
partial hydatidiformmole (PHM), placental mesenchymal dysplasia
(PMD), and recurrent hydatidiform mole [17,18].
CHM is associated with diandric diploidy without a maternal
contribution of the genome and may have a negative p57KIP2
immunostaining because the p57KIP2 gene or CDKN1C gene is
maternally expressed and paternally imprinted [19,20]. However,
in some cases of CHM, there is a positive p57KIP2 immuno-
staining because of the retention of a maternal chromosome 11
[21,22].
PHM is associated with a 2:1 ratio of paternal: maternal haploid
genomes because of diandric triploidy and has a positive p57KIP2
immunostaining in the presence of a maternal allele.
Recurrent hydatidiformmole is an autosomal recessive disorder
of which recurrent hydatidiform mole-1 (OMIM 231090) is caused
by the mutation of the gene NLRP7 (OMIM 609661) at 19q13
[23,24], and recurrent hydatidiform mole-2 (OMIM 614293) is
caused by themutation of the gene KHDC3L (OMIM 611687) at 6q13
[25,26].
PMD is associated with placentomegaly and many grape-like
vesicles, a preponderance of female, absence of trophoblastic pro-
liferation, presence of a normal-appearing fetus with fetal over-
growth or intrauterine growth restriction, a diploid karyotype, and
an association of BeckwitheWiedemann syndrome (BWS). PMD
can be caused by androgenetic/biparental mosaicism in the
placenta [27e36], BWS-associated epigenetic errors and/or chro-
mosomal abnormalities [29,35], paternal uniparental disomy 6
[37], VEGF over-expression [38], and VEGF-D abnormal expression
[39].
Furtado et al [40] suggested that microsatellite genotyping is a
useful method for rapid molar pregnancy testing to make a dif-
ferential diagnosis of CHM, PHM, PMD, and nonmolar pregnancy.
However, microsatellite genotyping has limitations in some cases
of familial hydatidiform mole, surrogate pregnancy, paternally
derived triploidy, and mosaicism for androgenetic and biparental
cell lines confused with PHM, and will require histology and p57
immunohistochemistry [40]. Microsatellite genotyping is rela-
tively inexpensive for diagnosing and classifying hydatidiform
mole, and can potentially identify genomic imbalances such as
common autosomal trisomies [40e48]. Recently, Hasegawa et al
[49] identiﬁed CHM pregnancy-associated microRNAs in maternal
plasma in CHM pregnancy and suggested a novel diagnostic,
prognostic or follow-up molecular marker in the clinical man-
agement of CHM.
The present case provides evidence for the usefulness of mi-
crosatellite genotyping for molar pregnancy testing and zygosity
testing in cases of prenatal diagnosis of placentomegaly associated
with many grape-like vesicles and a twin pregnancy with a living
fetus in the ﬁrst trimester.
Fig. 5. Representative electrophoretogram of quantitative ﬂuorescent polymerase chain reaction (QF-PCR) assays using informative polymorphic markers of D13S768 (13q21.1),
D18S877 (18q12.1), and D21S2049 (21q22.11). The result shows biparental inheritance in the normal fetus and complete paternal homozygosity in the complete hydatidiform mole
(CHM) of the abnormal fetus in all small tandem repeat (STR) markers, indicating dizygotic twinning and CHM of monospermy.
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